Objectives: FNABis a cytological procedure enabling the monitoring of inflammatory cells in the graft, morphological modification of parenchymal cells, and expression of antigens on aspirated cells. The aim of the study was to evaluate whether Daclizumab influences the composition of inflammatory infiltrate and expression of HLA-DR antigens and intercellular adhesive molecule ICAM-1 on parenchymal cells. Methods: Two groups of liver allograft recipients were included and they were treated with two different immunosuppressive protocols. The first group with quadruple immunosuppression therapy (Cyclosporine A, Mycophenolate mofetil, steroids, and Daclizumab).The second group with quadruple combination immunosuppression (Cyclosporine A. Azathioprine, steroids and ATG-Fresenius). FNAB and blood samples were collected simultaneously. Corrected increments of inflammatory cells were statistically evaluated as well as expression of HLA-DR antigens and ICAM-1 on parenchymal cells. Results: FNAB specimens from the Daclizumab group demonstrated significantly lower values of the total corrected increment, the corrected increment of monocytes, number of blast cells per slide, and a lower number of ICAM-1 expressing parenchymal cells. Conclusion:We summarise that Daclizumab significantly reduces inflammatory cells in liver graft, as well as expression of ICAM-1 on parenchymal cells.

Keywords: fine needle aspiration biopsy (FNAB), Daclizumab, Liver Transplantation